TY - JOUR T1 - Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection JF - medRxiv DO - 10.1101/2020.07.30.20165175 SP - 2020.07.30.20165175 AU - Jacob K. Files AU - Sushma Boppana AU - Mildred D. Perez AU - Sanghita Sarkar AU - Kelsey E. Lowman AU - Kai Qin AU - Sarah Sterrett AU - Eric Carlin AU - Anju Bansal AU - Steffanie Sabbaj AU - Dustin M. Long AU - Olaf Kutsch AU - James Kobie AU - Paul A. Goepfert AU - Nathan Erdmann Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/01/2020.07.30.20165175.abstract N2 - SARS-CoV-2 causes a wide spectrum of clinical manifestations and significant mortality. Studies investigating underlying immune characteristics are needed to understand disease pathogenesis and inform vaccine design. In this study, we examined immune cell subsets in hospitalized and non-hospitalized individuals. In hospitalized patients, many adaptive and innate immune cells were decreased in frequency compared to healthy and convalescent individuals, with the exception of B lymphocytes which increased. Our findings show increased frequencies of T-cell activation markers (CD69, Ox40, HLA-DR and CD154) in hospitalized patients, with other T-cell activation/exhaustion markers (CD25, PD-L1 and TIGIT) remaining elevated in hospitalized and non-hospitalized individuals. B cells had a similar pattern of activation/exhaustion, with increased frequency of CD69 and CD95 during hospitalization, followed by an increase in PD1 frequencies in non-hospitalized individuals. Interestingly, many of these changes were found to increase over time in non-hospitalized longitudinal samples, suggesting a prolonged period of immune dysregulation following SARS-CoV-2 infection. Changes in T-cell activation/exhaustion in non-hospitalized patients were found to positively correlate with age. Severely infected individuals had increased expression of activation and exhaustion markers. These data suggest a prolonged period of immune dysregulation following SARS-CoV-2 infection highlighting the need for additional studies investigating immune dysregulation in convalescent individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe University of Alabama at Birmingham provided all funds for this initial exploratory study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Alabama at Birmingham Institutional Review Board: IORG Registration # IRB00000196 (IRB 01) IORG Registration # IRB00000726 (IRB 02)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData were generated at University of Alabama at BIrmingham. Derived data supporting the findings of this study are available from the corresponding authors (NE/PAG) on request. ER -